organization · Reporting owner
5AM Co-Investors IV, L.P.
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aprea Therapeutics, Inc.
Report date October 05, 2020 · Filed October 08, 2020
Jointly reported with 5AM Ventures IV, L.P., 5AM Partners IV, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, DIEKMAN JOHN D, Schwab Andrew J., PARMAR KUSH, ROCKLAGE SCOTT M
Section 16 reporting ended · disclosed 2020-10-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 138,497 |
Reported balance
After 2020-10-05 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2020-10-05 · Sale · Disposed 175,000 · Balance 138,497 F1: Shares are held directly by 5AM Opportunities I, L.P. ("Opportunities"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities expressly disclaim status as a "group" for purposes of this Form 4. F2: 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities, except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,823,192 |
Reported balance
Holding disclosure · report date 2020-10-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,823,192 F3: Shares are held directly by 5AM Ventures IV, L.P. F4: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Dr. Scott M. Rocklage and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 75,965 |
Reported balance
Holding disclosure · report date 2020-10-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 75,965 F5: Shares are held directly by 5AM Co-Investors IV, L.P. F4: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Dr. Scott M. Rocklage and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held directly by 5AM Opportunities I, L.P. ("Opportunities"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities expressly disclaim status as a "group" for purposes of this Form 4.
F2: 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities, except to the extent of its or his pecuniary interest therein.
F3: Shares are held directly by 5AM Ventures IV, L.P.
F4: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Dr. Scott M. Rocklage and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.
F5: Shares are held directly by 5AM Co-Investors IV, L.P.
Crinetics Pharmaceuticals, Inc.
Report date June 21, 2019 · Filed June 25, 2019
Jointly reported with 5AM Ventures IV, L.P., 5AM Partners IV, LLC, ROCKLAGE SCOTT M, DIEKMAN JOHN D, Schwab Andrew J.
Section 16 reporting ended · disclosed 2019-06-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footote | 2,267,797 |
Reported balance
After 2019-06-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-06-21 · Sale · Disposed 240,000 · Balance 2,267,797 F1: These securities are held by by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footote | 94,489 |
Reported balance
After 2019-06-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-06-21 · Sale · Disposed 10,000 · Balance 94,489 F2: These securities are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Co-Investors IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held by by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
F2: These securities are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Co-Investors IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
IDEAYA Biosciences, Inc.
Report date November 11, 2020 · Filed November 14, 2020
Jointly reported with 5AM Ventures IV, L.P., 5AM Partners IV, LLC, 5AM Opportunities I, L.P., 5AM Opportunities I (GP), LLC, DIEKMAN JOHN D, Schwab Andrew J., ROCKLAGE SCOTT M
Section 16 reporting ended · disclosed 2020-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,187,428 |
Reported balance
After 2020-11-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-11-11 · Sale · Disposed 657,117 · Balance 2,187,428 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 91,142 |
Reported balance
After 2020-11-11 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-11-11 · Sale · Disposed 27,379 · Balance 91,142 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV" and, collectively with Ventures IV, the "5AM IV Funds"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 384,496 |
Reported balance
After 2020-11-11 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-11-11 · Sale · Disposed 115,504 · Balance 384,496 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held by 5AM Opportunities I, L.P. ("Opportunities I"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities I expressly disclaim status as a "group" for purposes of this Form 4. 5AM Opportunities I (GP), LLC ("Opportunities I GP") is the sole general partner of Opportunities I. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities I GP, and have shared voting and investment power over the shares beneficially owned by Opportunities I. Each of Opportunities I GP and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
F3: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV" and, collectively with Ventures IV, the "5AM IV Funds"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
F4: The shares are held by 5AM Opportunities I, L.P. ("Opportunities I"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities I expressly disclaim status as a "group" for purposes of this Form 4. 5AM Opportunities I (GP), LLC ("Opportunities I GP") is the sole general partner of Opportunities I. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities I GP, and have shared voting and investment power over the shares beneficially owned by Opportunities I. Each of Opportunities I GP and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.
Pear Therapeutics, Inc.
Report date April 10, 2023 · Filed April 12, 2023
Jointly reported with 5AM Partners IV, LLC, 5AM Ventures IV, L.P., 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M, Schwab Andrew J.
Section 16 reporting ended · disclosed 2023-04-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy 5AM Ventures IV, L.P. | 0 |
Reported balance
After 2023-04-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-04-10 · Sale · Disposed 12,836,489 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy 5AM Co-Investors IV, L.P. | 0 |
Reported balance
After 2023-04-10 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-04-10 · Sale · Disposed 534,855 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy 5AM Opportunities I, L.P. | 200,000 |
Reported balance
After 2023-04-10 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2023-04-10 · Sale · Disposed 3,172,769 · Balance 200,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.
F3: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.
F4: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein.
Q32 Bio Inc.
Report date December 22, 2020 · Filed December 29, 2020
Jointly reported with 5AM Ventures IV, L.P., 5AM Partners IV, LLC, DIEKMAN JOHN D, ROCKLAGE SCOTT M, Schwab Andrew J.
Section 16 reporting ended · disclosed 2020-12-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,354,484 |
Reported balance
After 2020-12-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-12-22 · Sale · Disposed 480,000 · Balance 4,354,484 F1: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 181,435 |
Reported balance
After 2020-12-22 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-12-22 · Sale · Disposed 20,000 · Balance 181,435 F2: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
F2: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
scPharmaceuticals Inc.
Report date October 06, 2022 · Filed October 11, 2022
Jointly reported with 5AM Partners IV, LLC, 5AM Opportunities I (GP), LLC, 5AM Opportunities I, L.P., 5AM Ventures IV, L.P., DIEKMAN JOHN D, ROCKLAGE SCOTT M, Schwab Andrew J.
Section 16 reporting ended · disclosed 2022-10-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy 5AM Ventures IV, L.P. | 2,231,601 |
Last balance in matching sequence
After 2022-10-10 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-10-06 · Sale · Disposed 30,457 · Balance 2,688,014 F1: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Row 4 · 2022-10-10 · Sale · Disposed 456,413 · Balance 2,231,601 F1: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy 5AM Co-Investors IV, L.P. | 92,983 |
Last balance in matching sequence
After 2022-10-10 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2022-10-06 · Sale · Disposed 1,269 · Balance 112,000 F2: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Row 5 · 2022-10-10 · Sale · Disposed 19,017 · Balance 92,983 F2: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy 5AM Opportunities I, L.P. | 410,268 |
Last balance in matching sequence
After 2022-10-10 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2022-10-06 · Sale · Disposed 5,808 · Balance 497,304 F3: Shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein. Row 6 · 2022-10-10 · Sale · Disposed 87,036 · Balance 410,268 F3: Shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.
F2: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.
F3: Shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2019 Filed Feb 23, 2019 01:06 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 18,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-010154 · a4.xml · nonDerivative · entry 2 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foototes Disclosed balance after: 110,683 F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Co-Investors IV, L.P. ("Co-Investors IV") without consideration to its partners. F4 · ownership.nature: These securities are held of record by Co-Investors IV. F8 · ownership.nature: Partners IV is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| February 20, 2019 Filed Feb 23, 2019 01:06 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 451,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-010154 · a4.xml · nonDerivative · entry 1 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foototes Disclosed balance after: 2,656,442 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Ventures IV, L.P. ("Ventures IV") without consideration to its partners. F2 · ownership.nature: These securities are held of record by Ventures IV. F8 · ownership.nature: Partners IV is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 00:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 10,486 | $21.88 | $229,381.25 |
DisclosureSEC source: 0001104659-19-003219 · a4.xml · nonDerivative · entry 2 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 129,483 F2 · ownership.nature: These securities are held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Following the transactions reported herein, 129,483 shares of Common Stock are held of record by Co-Investors IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 00:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 251,667 | $21.88 | $5,505,215.63 |
DisclosureSEC source: 0001104659-19-003219 · a4.xml · nonDerivative · entry 1 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 3,107,642 F1 · ownership.nature: These securities are held of record by 5AM Ventures IV, L.P. ("Ventures IV"). Following the transactions reported herein, 3,107,642 shares of Common Stock are held of record by Ventures IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:10 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 623 | $26.01 | $16,201.18 |
DisclosureSEC source: 0001104659-18-072619 · a4.xml · nonDerivative · entry 2 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 246,035 F2 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:10 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 14,952 | $26.01 | $388,828.26 |
DisclosureSEC source: 0001104659-18-072619 · a4.xml · nonDerivative · entry 1 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,904,884 F1 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:08 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 1,187 | $20.04 | $23,782.73 |
DisclosureSEC source: 0001104659-18-070148 · a4.xml · nonDerivative · entry 2 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 246,658 F2 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:08 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 28,495 | $20.04 | $570,925.82 |
DisclosureSEC source: 0001104659-18-070148 · a4.xml · nonDerivative · entry 1 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,919,836 F1 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 22:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 21,036 | $20.20 | $424,927.20 |
DisclosureSEC source: 0001104659-18-069431 · a4.xml · nonDerivative · entry 2 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 247,845 F2 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 22:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 504,864 | $20.20 | $10,198,252.80 |
DisclosureSEC source: 0001104659-18-069431 · a4.xml · nonDerivative · entry 1 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,948,331 F1 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | ConversionSeries B Preferred Stock · Derivative | 61,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · derivative · entry 10 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 18,802 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Following the transactions reported herein, 139,969 shares of Common Stock are held of record by Co-Investors IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | ConversionSeries A Preferred Stock · Derivative | 383,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · derivative · entry 9 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 116,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Following the transactions reported herein, 139,969 shares of Common Stock are held of record by Co-Investors IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | ConversionSeries B Preferred Stock · Derivative | 1,484,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · derivative · entry 8 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 451,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F1 · ownership.nature: These securities are held of record by 5AM Ventures IV, L.P. ("Ventures IV"). Following the transactions reported herein, 3,359,309 shares of Common Stock are held of record by Ventures IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | ConversionSeries A Preferred Stock · Derivative | 9,204,220 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · derivative · entry 7 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,797,635 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F4 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F1 · ownership.nature: These securities are held of record by 5AM Ventures IV, L.P. ("Ventures IV"). Following the transactions reported herein, 3,359,309 shares of Common Stock are held of record by Ventures IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | PurchaseCommon Stock | 4,600 | $17.00 | $78,200.00 |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · nonDerivative · entry 6 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 139,969 F2 · ownership.nature: These securities are held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Following the transactions reported herein, 139,969 shares of Common Stock are held of record by Co-Investors IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | PurchaseCommon Stock | 110,400 | $17.00 | $1,876,800.00 |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · nonDerivative · entry 5 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 3,359,309 F1 · ownership.nature: These securities are held of record by 5AM Ventures IV, L.P. ("Ventures IV"). Following the transactions reported herein, 3,359,309 shares of Common Stock are held of record by Ventures IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | ConversionCommon Stock | 18,802 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · nonDerivative · entry 4 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 135,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Following the transactions reported herein, 139,969 shares of Common Stock are held of record by Co-Investors IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | ConversionCommon Stock | 116,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · nonDerivative · entry 3 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 116,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Following the transactions reported herein, 139,969 shares of Common Stock are held of record by Co-Investors IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | ConversionCommon Stock | 451,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · nonDerivative · entry 2 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 3,248,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F1 · ownership.nature: These securities are held of record by 5AM Ventures IV, L.P. ("Ventures IV"). Following the transactions reported herein, 3,359,309 shares of Common Stock are held of record by Ventures IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 23:02 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | ConversionCommon Stock | 2,797,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046330 · a4.xml · nonDerivative · entry 1 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,797,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. F1 · ownership.nature: These securities are held of record by 5AM Ventures IV, L.P. ("Ventures IV"). Following the transactions reported herein, 3,359,309 shares of Common Stock are held of record by Ventures IV. F3 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:41 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionSeries B Preferred Stock · Derivative | 1,187,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-022462 · a4.xml · derivative · entry 3 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,187,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock. F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:41 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionSeries A Preferred Stock · Derivative | 4,204,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-022462 · a4.xml · derivative · entry 2 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 4,204,502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock. F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:41 UTC | Q32 Bio Inc. FIXX · Entity 5594 | ConversionCommon Stock | 5,392,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-022462 · a4.xml · nonDerivative · entry 1 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Partners IV, LLC · CIK 0001589314 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 6,722,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Following the transactions reported herein, includes 6,453,195 shares of Common Stock held of record by 5AM Ventures IV, L.P. ("Ventures IV") and 268,881 shares of Common Stock held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries B Preferred Stock · Derivative | 302,652 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · derivative · entry 10 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Co-Investors IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 42,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries A Preferred Stock · Derivative | 443,708 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · derivative · entry 9 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Co-Investors IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 61,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries B Preferred Stock · Derivative | 7,263,649 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · derivative · entry 8 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Ventures IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,011,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionSeries A Preferred Stock · Derivative | 10,649,003 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · derivative · entry 7 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Ventures IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,483,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F6 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | PurchaseCommon Stock | 26,190 | $14.00 | $366,660.00 |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · nonDerivative · entry 6 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Co-Investors IV, L.P. Disclosed balance after: 130,135 F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 42,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · nonDerivative · entry 5 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Co-Investors IV, L.P. Disclosed balance after: 103,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Represents the total number of shares of Common Stock received by 5AM Co-Investors IV, L.P., upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 61,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · nonDerivative · entry 4 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Co-Investors IV, L.P. Disclosed balance after: 61,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Represents the total number of shares of Common Stock received by 5AM Co-Investors IV, L.P., upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | PurchaseCommon Stock | 628,572 | $14.00 | $8,800,008.00 |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · nonDerivative · entry 3 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Ventures IV, L.P. Disclosed balance after: 3,123,302 F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 1,011,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · nonDerivative · entry 2 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Ventures IV, L.P. Disclosed balance after: 2,494,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Represents the total number of shares of Common Stock received by 5AM Ventures IV, L.P., upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
| November 21, 2017 Filed Nov 21, 2017 19:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | ConversionCommon Stock | 1,483,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-027189 · doc4.xml · nonDerivative · entry 1 5AM Partners IV, LLC · CIK 0001589314 · 10% owner 5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner 5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by 5AM Ventures IV, L.P. Disclosed balance after: 1,483,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by 5AM Ventures IV, L.P., upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: 5AM Partners IV, LLC is the general partner of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (the "5AM Funds"). Dr. John D. Diekman, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC. 5AM Partners IV, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by the 5AM Funds. Dr. Diekman, Mr. Schwab, and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially by the 5AM Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.